Why GLP-1 Ads Are Changing: What the FDA's New Marketing Rules Mean for You
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
If you have noticed that some telehealth companies are suddenly talking about their GLP-1 products differently, or their social media content has disappeared and come back looking vague, there is a reason. The FDA sent warning letters to 30 telehealth companies in February 2026 for making misleading marketing claims about compounded GLP-1 medications (FDA). This does not mean compounding is going away. It means companies have to be more honest about what they are selling.
Who This Helps
This article is for you if you have been getting a GLP-1 medication through a telehealth provider and noticed something changed recently. Maybe the ads look different. Maybe the way your provider describes your medication shifted. Maybe a company you follow went quiet for a while and came back with new messaging. It is also for anyone who saw a headline about FDA crackdowns and wants to understand what it actually means for their treatment.
Spoiler: compounding is not disappearing. But the way companies market compounded products is changing, and that is actually a good thing. GLP Winner tracks provider options with transparent pricing so you always know what you are getting.
What Actually Happened?
On March 3, 2026, the FDA publicly announced that it had sent warning letters to 30 telehealth companies. The letters were dated February 20. The companies were cited for how they marketed compounded GLP-1 products, not for the act of compounding itself (FDA).
This is an important distinction. The FDA did not say these companies cannot offer compounded GLP-1 medications. It said they cannot mislead people about what those medications are.
Some of the companies named include GenoGenix, Lovely Meds, Hello Cake, MEDVi, Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, and GoodGirlRx (Pharmaceutical Technology). Some of these companies are also listed as providers on GLP Winner. Being named in a warning letter does not mean a provider is unsafe. It means their marketing content made claims the FDA considers misleading. Each company was given 15 days to update their marketing and respond (FDA).
What Were Companies Doing Wrong?
The FDA identified three main types of marketing violations (FDA):
- Making "sameness" claims. Some companies implied their compounded products were the same as, or a cheaper version of, FDA-approved medications like Wegovy or Ozempic. The FDA requires companies to clearly distinguish compounded products from branded ones (FDA).
- Hiding where the medication comes from. Some companies put their own branding on the medication packaging, making it look like they manufactured the drug themselves. They did not. This makes it harder for you to know where your medication actually comes from (STAT News).
- Implying FDA approval where there is none. Some companies made safety or effectiveness claims that suggested their compounded products had been through the FDA approval process. Compounded products are not FDA-approved as finished drugs (Fierce Pharma).
In one serious case, GenoGenix was flagged for manufacturing problems. Three people needed emergency room treatment after taking GenoGenix products, and an unopened vial from the same batch contained excessive bacterial contamination (FairsOnline). This is a safety issue, not a marketing issue, and it is the kind of problem that makes accurate sourcing and transparency even more important.
Why This Matters If You Use a Telehealth Provider
You may have already noticed some of these changes in the real world. If a telehealth company you follow suddenly pulled ads, changed how they describe their GLP-1 products, or started using vaguer language, this is probably why. Companies are adjusting their messaging to stay within the FDA's rules.
That might feel unsettling if you are a customer, but it is actually a positive shift. It means the companies you work with are being pushed to be more truthful about what they offer. You deserve to know exactly what you are getting, where it comes from, and how it differs from FDA-approved brands. That transparency is what GLP Winner has always been about.
What About the Hims and Novo Nordisk Deal?
Around the same time the warning letters went out, one of the biggest names in telehealth, Hims & Hers, struck a deal with Novo Nordisk. The short version: Hims will now offer FDA-approved Ozempic and Wegovy products directly through its platform, including the new Wegovy pill (STAT News).
Here is what this deal actually changes. Hims agreed to stop advertising and marketing compounded GLP-1 products. But there is an exception: a doctor can still prescribe a compounded product if they determine it is medically necessary for a specific patient (Hims Investor Relations). So this is a change in how Hims talks about compounding, not a ban on compounding itself.
GLP Winner covered this deal in detail in our article on The Novo Nordisk and Hims Deal: What It Means for GLP-1 Pricing and Access. The takeaway: Hims is adding branded products to its lineup and changing its marketing. Compounded medications are still available through Hims when a prescriber determines they are needed. Eli Lilly has a similar arrangement with telehealth provider Ro.
These partnerships signal a broader trend in the industry. Major telehealth companies are adding FDA-approved products alongside compounded options and adjusting how they market both. GLP Winner tracks these shifts so you always have a clear picture of what each provider offers.
What This Means for You
If your telehealth provider's messaging has gotten vaguer, that does not mean your medication is going away or that the provider is in trouble. It likely means they are updating their marketing to follow the FDA's rules. You may also see companies offer FDA-approved branded products before compounded options, giving you more choices but also making you search a bit more for them as an option. The key is knowing what each option is and making an informed decision with your doctor.
Compounding Is Not Going Away
This is worth saying clearly: the FDA's enforcement actions are about marketing, not about shutting down compounding. Licensed compounding pharmacies still operate within the law, and compounded GLP-1 medications remain an option for many people (Venable LLP).
There are two types of licensed compounding pharmacies that operate within established regulatory frameworks:
- 503A pharmacies are licensed facilities that compound medications based on individual prescriptions from a licensed provider. They are regulated by state boards of pharmacy. Your doctor determines that a compounded product is right for your specific situation.
- 503B outsourcing facilities are registered with the FDA and subject to FDA manufacturing standards and inspections. They may produce larger quantities, but they still must meet strict quality requirements.
Both types operate under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. They are entirely different from the grey-market sellers or fly-by-night websites that the FDA is most concerned about (FDA). For a deeper look at the difference between these pharmacy types, see GLP Winner's article on 503A vs 503B compounding pharmacies.
If you are using a compounded GLP-1 from a licensed pharmacy and your doctor prescribed it for you, these warning letters do not change that. The letters are directed at how companies market their products, not at the pharmacy-level compounding that your prescription relies on.
How to Make Sure You Are Getting Your Medication from a Safe Source
Whether you choose an FDA-approved brand or a compounded product, where your medication comes from matters. Here are a few things to check:
- Ask your provider where your medication is compounded. A reputable provider will tell you the pharmacy name and whether it is a 503A or 503B facility.
- Look for pharmacies that test every batch for potency and sterility. This is standard at 503B outsourcing facilities and a good sign at any compounding pharmacy.
- Be cautious with products marketed "for research purposes." These are not intended for human use.
- If something seems too cheap or too vague, ask more questions. A trustworthy provider welcomes them.
The FDA has warned that some compounded semaglutide products may contain salt forms like semaglutide sodium or semaglutide acetate. The FDA says these are different active ingredients than those used in approved drugs, and the agency is not aware of any lawful basis for their use in compounding (FDA).
The FDA has also received reports of side effects, some requiring hospitalization, that may be related to dosing errors with compounded semaglutide injectable products (FDA). This is why knowing your source matters.
GLP Winner helps you compare providers, check pricing, see which pharmacies they work with, and find options that accept HSA/FSA payments. Having all of that in one place makes it easier to feel confident about where your medication is coming from.
Language to Watch For
The FDA is pushing companies to be more accurate and truthful in how they describe compounded GLP-1 products. That benefits everyone. But it also means you should know what red-flag marketing looks like so you can spot it yourself:
- "Same as Ozempic" or "same as Wegovy" . Compounded GLP-1 products are not FDA-approved and cannot be marketed as the same as branded medications (FDA).
- "Generic semaglutide" or "generic tirzepatide" . There are no FDA-approved generic versions of these medications. Compounded products are not generics.
- "FDA-registered facility" . Registration is a basic legal requirement for any facility that handles drugs. It does not mean the FDA has reviewed or approved the products made there.
- "Clinically proven" when describing a compounded product . Compounded products have not been through the FDA clinical trial process.
- "Same active ingredient" . The FDA has warned that some compounded products use semaglutide salt forms that are different active ingredients than those in approved drugs (FDA).
Seeing these phrases does not automatically mean a provider is bad. It means their marketing team needs to update their language. And now, the FDA is making sure they do.
Final Takeaway
The big picture here is simple. The FDA wants companies to be honest about what they sell. Compounded GLP-1 medications are still available. Licensed pharmacies are still operating. Your prescriber can still determine that a compounded product is the right fit for you.
What is changing is the marketing. The ads that implied compounded products were the same as Wegovy or Ozempic are being cleaned up. The language is getting more accurate. And that is a win for anyone trying to make a clear, informed decision about their health.
If you are looking for a provider, whether for an FDA-approved brand or a compounded option, start by understanding what each one actually offers. Ask questions. Compare prices. And use tools like GLP Winner to cut through the noise and see what is real.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
Which GLP-1 medications are FDA-approved for weight management vs diabetes? Clear labels, approved uses, and common misconceptions explained.
The FDA issued a warning about counterfeit Ozempic, research peptides and retatrutide . Medications should be prescribed and filled with state licensed pharmacies
Novo Nordisk and Hims struck a deal on Ozempic and Wegovy pricing. See what it means for GLP-1 costs, compounded access, and your options.
Categories
Curated by
